Financials data is unavailable for this security.
View more
Year on year Sino Biopharmaceutical Ltd grew revenues 10.18% from 26.20bn to 28.87bn while net income improved 50.08% from 2.33bn to 3.50bn.
| Gross margin | 81.77% |
|---|---|
| Net profit margin | 22.15% |
| Operating margin | 23.07% |
| Return on assets | 9.56% |
|---|---|
| Return on equity | 11.77% |
| Return on investment | 18.52% |
More ▼
Cash flow in CNYView more
In 2024, cash reserves at Sino Biopharmaceutical Ltd fell by 1.27bn. However, the company earned 6.62bn from its operations for a Cash Flow Margin of 22.92%. In addition the company used 1.71bn on investing activities and also paid 6.32bn in financing cash flows.
| Cash flow per share | 0.5115 |
|---|---|
| Price/Cash flow per share | 12.06 |
| Book value per share | 2.13 |
|---|---|
| Tangible book value per share | 1.93 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.36 |
|---|---|
| Quick ratio | 1.28 |
| Total debt/total equity | 0.3582 |
|---|---|
| Total debt/total capital | 0.2071 |
More ▼
Growth rates in CNY
SmartText is unavailable
| Div yield(5 year avg) | 1.64% |
|---|---|
| Div growth rate (5 year) | 6.66% |
| Payout ratio (TTM) | 38.18% |
| EPS growth(5 years) | -6.50 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 99.20 |
More ▼
